Watanabe and colleagues [20] recognized IGSF11 as a new therapeutic target for gastric cancer and found two peptide sequences originating from IGSF11 that could provoke cytotoxic T lymphocyte (CTL) responses directed at IGSF11-expressing gastric cancer cells in an HLA-A*0201-restricted manner. This evidence concerns the gene HLA-A and gastric cancer.